Best Practice and Physician-Driven Networks
Lower prices often didn't result in increased market share. As a result, in the early 1990s we saw a kind of backlash against the bigger-is-better mentality, as suppliers regarded skeptically any group that had a membership too large to effectively manage, while rewarding (with better prices) those groups, particularly investor-owned hospital systems, that could mandate compliance.
You may also be interested in...
Just five weeks before the US election, a Medtech Insight analysis shows medical device companies are spending more on Democrat Joe Biden’s campaign than on Republican Donald Trump’s.
Denmark’s Orphazyme has raised more funds to market its lead product, the heat shock protein amplifier, arimoclomol, in the US and Europe, and to evaluate the compound for other lysosomal storage and neurodegenerative disorders.
Pacific Biosciences of California and Aziyo Biologics both acquire new finance chiefs; Illumina hires a new chief marketing officer; WishBone Medical president moves over to take helm at Electromedical Products International; and more.